17 unknown, 7 completed, 7 not yet recruiting, 3 recruiting. 26 Phase 2, 6 Phase 1, 3 Not applicable, 3 Phase 3, 1 Phase 4.
Follow Apatinib Mesylate Tablets: new trials by email Literature Review of Apatinib Mesylate Tablets trials Research Report on Apatinib Mesylate Tablets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC Retlirafusp alfa, zeprumetostat, apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 55 | 2026-10-01 | 2026-10-14 |
| A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets - Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 120 | 2026-07-01 | 2026-07-02 |
| A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC - HCC - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | Henan Cancer Hospital | 208 | 2026-05-25 | 2026-06-01 |
| Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD Adebrelimab Injection, Apatinib Mesylate Tablets - Small Cell Lung Carcinoma | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 44 | 2026-01-31 | 2026-01-22 |
| Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer Metronomic capecitabine, Camrelizumab, Apatinib Mesylate Tablets - Metastatic Pancreatic Carcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 43 | 2025-01-15 | 2025-01-06 |
| Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 37 | 2024-12-01 | 2024-01-03 |
| Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis Adebrelimab, Apatinib, Etoposide - HER2-negative Breast Cancer Brain Metastases | Phase 2 | Recruiting | Beijing 302 Hospital | 30 | 2024-10-10 | 2024-12-10 |
| Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin - Small Cell Lung Cancer | Not applicable | Recruiting | Yunpeng Liu | 38 | 2024-08-09 | 2025-01-06 |
| Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach Apatinib, Oxaliplatin, S1 - Gastric Cancer | Phase 2 | Withdrawn | Peking University | 2021-05-11 | 2025-02-21 | |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride Injection - Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 3 | Unknown | RemeGen Co., Ltd. | 351 | 2021-03-24 | 2023-12-21 |
| Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) Apatinib Mesylate Tablets, Bevacizumab Injection - Colorectal Neoplasms | Not applicable | Suspended | Shenzhen People's Hospital | 40 | 2020-10-22 | 2023-06-29 |
| Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors radiotherapy, irinotecan liposome, apatinib - Solid Tumor | Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2020-09-01 | 2020-09-30 |
| Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer Apatinib S-1 - Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2019-10-01 | 2019-10-16 |
| Treatment of Carrying TP53 Harmful Mutations Fluzoparib combined with Apatinib - Advanced Cancer | Phase 1 | Unknown | Tianjin Medical University Second Hospital | 60 | 2019-07-01 | 2019-04-25 |
| Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children Apatinib mesylate tablets, Three-dimensional conformal intensity modulation - Childhood Rhabdomyosarcoma | Phase 1 / Phase 2 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 48 | 2019-01-01 | 2019-03-11 |
| Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) Apatinib Mesylate Tablets, Bevacizumab Injection - Colorectal Neoplasms, Intestinal Neoplasms | Phase 2 | Unknown | Shenzhen People's Hospital | 80 | 2018-05-23 | 2019-01-23 |
| Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer Apatinib, SBRT - Breast Cancer | Phase 2 | Unknown | Yan Li | 30 | 2018-03-15 | 2018-03-07 |
| A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma Apatinib, Temozolomide - Advanced Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 30 | 2018-01-08 | 2018-02-05 |
| A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium Capsules - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 38 | 2017-10-01 | 2023-10-17 |
Showing 20 of 37. Sign in to see all of them.
Stomach Neoplasms (7) · Carcinoma, Hepatocellular (3) · Sarcoma (3) · Small Cell Lung Carcinoma (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Digestive System Neoplasms (1) · Gastrointestinal Neoplasms (1)
Tianjin Medical University Cancer Institute and Hospital (5) · Peking University Cancer Hospital & Institute (3) · Jiangsu HengRui Medicine Co., Ltd. (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Shenzhen People's Hospital (2) · Beijing 302 Hospital (1) · Chinese PLA General Hospital (1) · Fudan University (1) · Fujian Medical University (1) · Henan Cancer Hospital (1) · Peking Union Medical College Hospital (1) · Peking University (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · RemeGen Co., Ltd. (1)
China (29)
Baorui Baorui Liu, Doctor (1) · Chen Yu (1) · Hai-tao Zhao (1) · Haitao Wang, Ph.D (1) · Han Liang, Master (1) · Huiping Li, MD (1) · Jilong Yang, M.D., Ph.D. (1) · Jun Guo, MD，PHD (1) · Jun Zhao (1) · Li Liang, Prof. M.D. (1) · Lin Chen (1) · Mawei Jiang, MD (1) · Mei Feng (1) · Qiong Wu, M.D.,Ph.D (1)
PMID 30082170, PMID 32827353, PMID 33012286, PMID 33145266, PMID 35190519, PMID 36267741, PMID 37056765